Immutep To Present New Phase IIb Data In PD-L1 Negative Head And Neck Cancer At ESMO Immuno-Oncology 2024
Portfolio Pulse from Benzinga Newsdesk
Immutep Limited will present new Phase IIb trial data for its LAG-3 immunotherapy in PD-L1 negative head and neck cancer at the ESMO Immuno-Oncology Congress 2024.
October 28, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep Limited is set to present new data from its Phase IIb trial for LAG-3 immunotherapy in PD-L1 negative head and neck cancer at the ESMO I-O Congress 2024.
The announcement of new trial data presentation at a major oncology congress could positively impact Immutep's stock as it highlights progress in their LAG-3 immunotherapy development. This could attract investor interest and confidence in the company's pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90